On July 27, 2020, Summit Therapeutics plc (the “Company”) announced that it is convening a court meeting of shareholders (the “Court Meeting”) and a general meeting of shareholders (the “General Meeting” and together with the Court Meeting, the “Meetings”) to be held at 1:30 p.m. BST and 1:40 p.m. BST, respectively, on August 19, 2020 in connection with the Company’s proposed change of corporate domicile to the United States, to be effected by a United Kingdom court-approved scheme of arrangement (the “Scheme”), and to consider and, if thought fit, pass resolutions to, inter alia, approve the implementation of the Scheme, a reduction of capital of the Company, certain amendments to the Company’s articles of association and the 2020 Stock Incentive Plan and the 2020 Employee Stock Purchase Plan of Summit Therapeutics Inc., a Delaware corporation that will be the new U.S. holding company following effectiveness of the Scheme, if approved by shareholders and subsequently sanctioned by the Court. The Scheme is expected to become effective on September 18, 2020.
The circular, including notices convening the Meetings, that will be sent to the Company’s shareholders is attached as Exhibit 99.1 to this Form 6-K and is incorporated herein by reference.
This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-232074).
